UM  > Institute of Chinese Medical Sciences
Opportunities and Challenges of Multinational Pharmaceutical Enterprises in Transforming Pharmaceutical Market in China
Linfeng Hu1; Zhong Yu2; Qingwen Yuan3; Yuanjia Hu3; Carolina Oi Lam Ung3
2018
Source PublicationTherapeutic innovation & regulatory science
ISSN2168-4790
Volume53Issue:2Pages:207-214
Abstract

The surging costs of health care in China is highly related to the high expenses in pharmaceutical costs. Since the Government of China launched the health care reform in 2009, the issue of growing pharmaceutical expenditure continues to grasp policy makers’ attention. Since 2015, an ongoing series of drug-related policies have been revised or developed, resulting in profound impact on the overall pharmaceutical market in China, and the dynamic is still evolving. As China has become the second largest pharmaceutical market in the world, any volatility in the Chinese pharmaceutical market may have great implications to multinational pharmaceutical markets that have had their products launched in China or plan to extend their business to the Chinese market. Based on a comprehensive analysis of the most recent health care reform policies in China, the objectives of this study were to identify the major opportunities appealed to and the challenges confronted by multinational pharmaceutical enterprises in the current Chinese pharmaceutical market.

KeywordChina Health Care Reform Multinational Pharmaceutical Enterprises Pharmaceutical Market
DOIhttps://doi.org/10.1177/2168479018772820
Indexed BySCIE
Language英语
WOS Research AreaMedical Informatics ; Pharmacology & Pharmacy
WOS SubjectMedical Informatics ; Pharmacology & Pharmacy
WOS IDWOS:000462049200008
Fulltext Access
Citation statistics
Cited Times [WOS]:0   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionInstitute of Chinese Medical Sciences
Corresponding AuthorCarolina Oi Lam Ung
Affiliation1.Chongqing Key Laboratory of Medicinal Resources in the Three Gorges Reservoir Region, School of Biological and Chemical Engineering, Chongqing University of Education, Chongqing, China
2.Chongqing Huapont Pharmaceutical Co, Ltd, Chongqing, China
3.State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China
Corresponding Author AffilicationInstitute of Chinese Medical Sciences
Recommended Citation
GB/T 7714
Linfeng Hu,Zhong Yu,Qingwen Yuan,et al. Opportunities and Challenges of Multinational Pharmaceutical Enterprises in Transforming Pharmaceutical Market in China[J]. Therapeutic innovation & regulatory science,2018,53(2):207-214.
APA Linfeng Hu,Zhong Yu,Qingwen Yuan,Yuanjia Hu,&Carolina Oi Lam Ung.(2018).Opportunities and Challenges of Multinational Pharmaceutical Enterprises in Transforming Pharmaceutical Market in China.Therapeutic innovation & regulatory science,53(2),207-214.
MLA Linfeng Hu,et al."Opportunities and Challenges of Multinational Pharmaceutical Enterprises in Transforming Pharmaceutical Market in China".Therapeutic innovation & regulatory science 53.2(2018):207-214.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Linfeng Hu]'s Articles
[Zhong Yu]'s Articles
[Qingwen Yuan]'s Articles
Baidu academic
Similar articles in Baidu academic
[Linfeng Hu]'s Articles
[Zhong Yu]'s Articles
[Qingwen Yuan]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Linfeng Hu]'s Articles
[Zhong Yu]'s Articles
[Qingwen Yuan]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.